IP Library Granted Patent US 8,647,618
Granted Patent B2
US 8,647,618 · App. 13/524,503 · Granted Feb 11, 2014

Method of cancer treatment

Inventors: Arnold S. Leonard (Minneapolis, MN); Daniel A. Saltzman (Mendota Heights, MN); Mark J. Mueller (Spooner, WI)
Assignee: Cureium Therapeutics LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,647,618
App. No.
13/524,503
Granted
Feb 11, 2014
Kind
B2
Abstract

A method and composition for treating cancer comprising administering to a patient an effective amount of attenuated Salmonella typhimurium containing a plasmid carrying the coding sequence encoding a truncated human interleukin-2 and optionally an oil containing a high antioxidant concentration.

Claims (6)

1. An anti-tumor agent comprising an effective amount of attenuated Salmonella typhimurium containing a plasmid carrying a coding sequence encoding a truncated human interleukin-2, wherein the truncated human interleukin-2 consists of the amino acid sequence shown in SEQ ID NO:2.

2. The anti-tumor agent of claim 1 wherein the plasmid comprises SEQ ID NO:5.

3. The anti-tumor agent of claim 1 wherein the plasmid comprises SEQ ID NO:1.

4. An anti-tumor agent comprising an affective amount of attenuated Salmonella typhimurium containing a coding sequence encoding the truncated human interleukin-2 of SEQ ID NO:2, wherein the coding sequence has 95-100% identity to SEQ ID NO:1.

5. The anti-tumor agent of claims 1 , 2 , 3 or 4 wherein the attenuated Salmonella typhimurium containing the coding sequence encoding the truncated human interleukin-2 lacks the cyclic AMP and cAMP receptor protein.

6. The anti-tumor agent of claim 5 wherein the attenuated Salmonella typhimurium lacks DNA encoding enzyme aspartate semialdehyde dehydrogenase and the plasmid encodes said dehydrogenase and wherein the plasmid also encodes said truncated human interleukin-2.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2021
From: SALTZMAN, DANIEL A, M.D.
To: SALSPERA, LLC
Reel/Frame 056660/0205 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2021
From: CUREIUM HEALTHCARE HOLDINGS, INC.
To: SALTZMAN, DANIEL A, M.D.
Reel/Frame 056660/0305 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2021
From: LEONARD, ARNOLD S.; SALTZMAN, DANIEL A.; MUELLER, MARK J.
To: BOTANIC OIL INNOVATIONS, INC.
Reel/Frame 055545/0298 →
CHANGE OF NAME Recorded Mar 10, 2021
From: BOTANIC OIL INNOVATIONS, INC.
To: CUREIUM HEALTHCARE HOLDINGS, INC.
Reel/Frame 055557/0818 →
Continuity (3)
Continuation 12425927 · Apr 17, 2009
Continuation In Part 10834587 · Apr 29, 2004
Related Publication 20130045525A1 · Feb 21, 2013